Senior Manager / Associate Director of Human Resources, Orbital Therapeutics
Office located in Cambridge, MA
Enhancing RNA-based medicines
Open for applications
Enhancing RNA-based medicines
21-100 employees
Open for applications
Office located in Cambridge, MA
21-100 employees
Company mission
To unleash the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible.
Jump to section
Company mission
To unleash the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible.
367% employee growth in 12 months
Our take
Orbital Therapeutics is building a first-of-its-kind RNA platform that is set to expand the applicability of RNA-based medicines across a range of human diseases, next-generation vaccines, immunomodulation, and protein replacement. Operating at the intersection of RNA technology delivery methods, data science, and automation, the company is well set to disrupt the industry with its innovative tech.
The vast potential of RNA-based therapeutics has the ability to alter the future of medicine and how diseases are treated, however, there are various barriers that keep companies from being able to deliver on the opportunities afforded by RNA medicines. Orbital was founded to provide such companies with the know-how and technological and biological insights needed to reach the full potential of RBA-based medicines.
The company has raised significant capital, recently led by ARCH Venture Partners, to advance its portfolio of programmable RNA to expand overall RNA -based applications. With a platform capable of changing how diseases are treated around the globe, Orbital is well set to see growth.
Freddie
Company Specialist at Welcome to the Jungle
Company values
- Innovate without boundaries, with curiosity and scientific excellence
- Create a diverse community where everyone from everywhere belongs and is heard
- Lead with mutual respect guided by humility and grace
Funding (1 round)
Apr 2023
$270m
SERIES A
Total funding: $270m
This company has top investors
Leadership
Current President of Beam Therapeutics where they had previously served as CSO, and Board Member at Dewpoint Therapeutics. Former CSO (Infectious Diseases) at Moderna.
John Maraganore, Ph.D.
(Chairman)Former CEO of Alnylam Pharmaceuticals.
Kristina Burow
(Director)Managing Director of ARCH Venture Partners.
Carol Suh
(Director & Board Member)Partner at ARCH Venture Partners. Co-Founder & CSO of Neumora.